Joanne Quan Sells 6,969 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 6,969 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $45.86, for a total value of $319,598.34. Following the completion of the transaction, the insider now directly owns 5,649 shares in the company, valued at approximately $259,063.14. This represents a 55.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Mirum Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ:MIRM traded up $1.03 during trading on Tuesday, hitting $47.98. The company had a trading volume of 430,899 shares, compared to its average volume of 489,433. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -23.75 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a fifty day simple moving average of $43.48 and a two-hundred day simple moving average of $41.27. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. During the same period last year, the company earned ($0.57) earnings per share. Mirum Pharmaceuticals’s revenue was up 89.4% on a year-over-year basis. As a group, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. lifted its stake in Mirum Pharmaceuticals by 1.2% in the third quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock worth $256,245,000 after purchasing an additional 75,000 shares during the last quarter. State Street Corp lifted its stake in shares of Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after acquiring an additional 297,511 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Mirum Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after acquiring an additional 29,017 shares during the period. Lord Abbett & CO. LLC purchased a new position in Mirum Pharmaceuticals during the 3rd quarter valued at $28,913,000. Finally, Clearbridge Investments LLC grew its position in Mirum Pharmaceuticals by 165.5% in the 2nd quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after acquiring an additional 436,349 shares during the last quarter.

Wall Street Analysts Forecast Growth

MIRM has been the topic of several recent analyst reports. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. HC Wainwright reiterated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners raised their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, Citigroup boosted their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.